{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:52:13Z","timestamp":1791849133152,"version":"4.3.4"},"reference-count":34,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Basic Clin Pharma Tox"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Migraine is a common disabling disorder, and optimising affordable preventive treatments remains highly relevant. Candesartan is an effective and well\u2010tolerated preventive treatment, but little is known about its dose\u2010concentration\u2013response relationships. We explored these relationships using data from the MigriNor study, a prospective observational cohort of adults with episodic or chronic migraine initiating oral preventive treatment. A total of 166 participants using candesartan were included (median age 35\u2009years; 89% female). Participants completed a daily electronic headache diary during a 4\u2010week baseline and 12\u2010week follow\u2010up period with accompanying blood sampling. Dosing regimen was flexible. No differences in adverse drug reactions (ADRs) or treatment acceptability were observed between participants starting 4\u2009versus 8\u2009mg. Substantial interindividual variability in serum concentrations was observed. Higher serum concentrations were associated with lower odds of headache attacks (OR = 0.97, 95% CI = 0.96\u20130.98,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001) and migraine attacks (OR = 0.98, 95% CI = 0.97\u20130.99,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.005). Interquartile ranges of serum concentrations among \u2265\u200930% and \u2265\u200950% responders were 62.9\u2013141.2\u2009and 62.3\u2013129.3\u2009nmol\/L, respectively, suggesting preliminary therapeutic reference ranges. Serum concentration was not associated with ADRs or treatment acceptability. Interpretation is limited by the flexible dosing design, and studies with fixed dosing regimens are warranted.\n                  <\/jats:p>","DOI":"10.1111\/bcpt.70322","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:16:24Z","timestamp":1791846984000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Serum Concentration Relationships of Candesartan in Migraine Prevention"],"prefix":"10.1111","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-7810-7882","authenticated-orcid":false,"given":"Hedda Skogum","family":"Riise","sequence":"first","affiliation":[{"name":"Norwegian Centre for Headache Research (NorHead) Norwegian University of Science and Technology (NTNU)  Trondheim Norway"},{"name":"Department of Neurology and Neurophysiology St. Olavs Hospital, Trondheim University Hospital  Trondheim Norway"},{"name":"Department of Neuromedicine and Movement Sciences, Faculty of Medicine and Health Sciences Norwegian University of Science and Technology (NTNU)  Trondheim Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2763-6343","authenticated-orcid":false,"given":"Melanie","family":"Simpson","sequence":"additional","affiliation":[{"name":"Department of Public Health and Nursing, Faculty of Medicine and Health Sciences Norwegian University of Science and Technology (NTNU)  Trondheim Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3566-3328","authenticated-orcid":false,"given":"Ketil Arne","family":"Espnes","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology St. Olavs Hospital, Trondheim University Hospital  Trondheim Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6059-0151","authenticated-orcid":false,"given":"Erling Andreas","family":"Tronvik","sequence":"additional","affiliation":[{"name":"Norwegian Centre for Headache Research (NorHead) Norwegian University of Science and Technology (NTNU)  Trondheim Norway"},{"name":"Department of Neurology and Neurophysiology St. Olavs Hospital, Trondheim University Hospital  Trondheim Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas Kattem","family":"Hus\u00f8y","sequence":"additional","affiliation":[{"name":"Norwegian Centre for Headache Research (NorHead) Norwegian University of Science and Technology (NTNU)  Trondheim Norway"},{"name":"Department of Neurology and Neurophysiology St. Olavs Hospital, Trondheim University Hospital  Trondheim Norway"},{"name":"Department of Neuromedicine and Movement Sciences, Faculty of Medicine and Health Sciences Norwegian University of Science and Technology (NTNU)  Trondheim Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise R.","family":"\u00d8ie","sequence":"additional","affiliation":[{"name":"Norwegian Centre for Headache Research (NorHead) Norwegian University of Science and Technology (NTNU)  Trondheim Norway"},{"name":"Department of Neurology and Neurophysiology St. Olavs Hospital, Trondheim University Hospital  Trondheim Norway"},{"name":"Department of Neuromedicine and Movement Sciences, Faculty of Medicine and Health Sciences Norwegian University of Science and Technology (NTNU)  Trondheim Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anker","family":"Stubberud","sequence":"additional","affiliation":[{"name":"Norwegian Centre for Headache Research (NorHead) Norwegian University of Science and Technology (NTNU)  Trondheim Norway"},{"name":"Department of Neuromedicine and Movement Sciences, Faculty of Medicine and Health Sciences Norwegian University of Science and Technology (NTNU)  Trondheim Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil","family":"Kofoed","sequence":"additional","affiliation":[{"name":"Faculty of Information Technology and Electrical Engineering Norwegian University of Science and Technology (NTNU)  Trondheim Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora Harsvik","family":"Alstad","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences Norwegian University of Science and Technology (NTNU)  Trondheim Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedda Hoff","family":"Hagen","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurophysiology St. Olavs Hospital, Trondheim University Hospital  Trondheim Norway"},{"name":"Faculty of Medicine and Health Sciences Norwegian University of Science and Technology (NTNU)  Trondheim Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maren Guldteig","family":"Lien","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences Norwegian University of Science and Technology (NTNU)  Trondheim Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Larsen","family":"Stavseng","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health Sciences Norwegian University of Science and Technology (NTNU)  Trondheim Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella Rian","family":"S\u00e6ther","sequence":"additional","affiliation":[{"name":"Department of Neurology and Neurophysiology St. Olavs Hospital, Trondheim University Hospital  Trondheim Norway"},{"name":"Faculty of Medicine and Health Sciences Norwegian University of Science and Technology (NTNU)  Trondheim Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tore","family":"Wergeland","sequence":"additional","affiliation":[{"name":"Norwegian Centre for Headache Research (NorHead) Norwegian University of Science and Technology (NTNU)  Trondheim Norway"},{"name":"Department of Neurology and Neurophysiology St. Olavs Hospital, Trondheim University Hospital  Trondheim Norway"},{"name":"Department of Neuromedicine and Movement Sciences, Faculty of Medicine and Health Sciences Norwegian University of Science and Technology (NTNU)  Trondheim Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"issue":"12","key":"e_1_2_10_2_1","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S1474-4422(25)00402-8","article-title":"Global, Regional, and National Burden of Headache Disorders, 1990\u20102023: A Systematic Analysis for the Global Burden of Disease Study 2023","volume":"24","year":"2025","journal-title":"Lancet Neurology"},{"issue":"4","key":"e_1_2_10_3_1","doi-asserted-by":"crossref","DOI":"10.1177\/03331024251321500","article-title":"Evidence\u2010Based Guidelines for the Pharmacological Treatment of Migraine, Summary Version","volume":"45","author":"Ornello R.","year":"2025","journal-title":"Cephalalgia"},{"issue":"1","key":"e_1_2_10_4_1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.289.1.65","article-title":"Prophylactic Treatment of Migraine With an Angiotensin II ReceptorBlocker: A Randomized Controlled Trial","volume":"289","author":"Tronvik E.","year":"2003","journal-title":"Journal of the American Medical Association"},{"issue":"7","key":"e_1_2_10_5_1","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1177\/0333102413515348","article-title":"A Comparative Study of Candesartan Versus Propranolol for Migraine Prophylaxis: A Randomised, Triple\u2010Blind, Placebo\u2010Controlled, Double Cross\u2010Over Study","volume":"34","author":"Stovner L. J.","year":"2014","journal-title":"Cephalalgia"},{"issue":"10","key":"e_1_2_10_6_1","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S1474-4422(25)00269-8","article-title":"Candesartan Versus Placebo for Migraine Prevention in Patients With Episodic Migraine: A Randomised, Triple\u2010Blind, Placebo\u2010Controlled, Phase 2 Trial","volume":"24","author":"\u00d8ie L. R.","year":"2025","journal-title":"Lancet Neurology"},{"issue":"4","key":"e_1_2_10_7_1","doi-asserted-by":"crossref","first-page":"333102424124883","DOI":"10.1177\/03331024241248833","article-title":"CandeSpartan Study: Candesartan Spanish Response\u2010Prediction and Tolerability Study in Migraine","volume":"44","author":"Garc\u00eda\u2010Azor\u00edn D.","year":"2024","journal-title":"Cephalalgia"},{"key":"e_1_2_10_8_1","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1111\/head.70061","article-title":"Effectiveness and Acceptability of Oral Migraine Preventives: A Prospective, Observational Study","volume":"66","author":"Riise H. S.","year":"2026","journal-title":"Headache"},{"issue":"4","key":"e_1_2_10_9_1","doi-asserted-by":"crossref","DOI":"10.1177\/03331024231159366","article-title":"Evaluating the Efficacy of CGRP mAbs and Gepants for the Preventive Treatment of Migraine: A Systematic Review and Network Meta\u2010Analysis of Phase 3 Randomised Controlled Trials","volume":"43","author":"Haghdoost F.","year":"2023","journal-title":"Cephalalgia"},{"issue":"3","key":"e_1_2_10_10_1","doi-asserted-by":"crossref","DOI":"10.1177\/03331024231152169","article-title":"Safety and Tolerability of Monoclonal Antibodies Targeting the CGRP Pathway and Gepants in Migraine Prevention: A Systematic Review and Network Meta\u2010Analysis","volume":"43","author":"Messina R.","year":"2023","journal-title":"Cephalalgia"},{"issue":"1","key":"e_1_2_10_11_1","first-page":"9","article-title":"Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017","volume":"51","author":"Hiemke C.","year":"2018","journal-title":"Pharmacopsychiatry"},{"issue":"21","key":"e_1_2_10_12_1","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.4045\/tidsskr.12.0383","article-title":"Therapeutic Drug Monitoring (TDM) Repertoire in Norway","volume":"132","author":"Westin A. A.","year":"2012","journal-title":"Tidsskrift for den Norske L\u00e6geforening"},{"issue":"1","key":"e_1_2_10_13_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2165\/00003088-200241010-00002","article-title":"Clinical Pharmacokinetics of Candesartan","volume":"41","author":"Gleiter C. H.","year":"2002","journal-title":"Clinical Pharmacokinetics"},{"key":"e_1_2_10_14_1","unstructured":"Limited AP \u201cCandesartan Cilexetil 8 mg Tablets: Summary of Product Characteristics (SmPC)\u201c (2024) https:\/\/www.medicines.org.uk\/emc\/product\/14555\/smpc."},{"issue":"2","key":"e_1_2_10_15_1","first-page":"S19","article-title":"Pharmacokinetics of Candesartan After Single and Repeated Doses of Candesartan Cilexetil in Young and Elderly Healthy Volunteers","volume":"11","author":"H\u00fcbner R.","year":"1997","journal-title":"Journal of Human Hypertension"},{"issue":"12","key":"e_1_2_10_16_1","doi-asserted-by":"crossref","first-page":"750","DOI":"10.5414\/CP201528","article-title":"Pharmacokinetic Interaction Study With Fixed High Dose Combinations of Candesartan Cilexetil and Hydrochlorothiazide","volume":"49","author":"Aberg J. G.","year":"2011","journal-title":"International Journal of Clinical Pharmacology and Therapeutics"},{"key":"e_1_2_10_17_1","first-page":"322","volume-title":"Disposition of Toxic Drugs and Chemicals in Man","author":"Baselt R. C.","year":"2020"},{"issue":"5","key":"e_1_2_10_18_1","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40263-017-0430-3","article-title":"Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine","volume":"31","author":"Tfelt\u2010Hansen P.","year":"2017","journal-title":"CNS Drugs"},{"issue":"6","key":"e_1_2_10_19_1","doi-asserted-by":"crossref","DOI":"10.1111\/bcpt.70159","article-title":"BCPT 2026 Policy for Experimental and Clinical Studies","volume":"137","author":"Tveden\u2010Nyborg P.","year":"2025","journal-title":"Basic & Clinical Pharmacology & Toxicology"},{"key":"e_1_2_10_20_1","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.4103\/sja.SJA_543_18","article-title":"The STROBE Guidelines","volume":"13","author":"Cuschieri S.","year":"2019","journal-title":"Saudi Journal of Anaesthesia"},{"issue":"1","key":"e_1_2_10_21_1","first-page":"1","article-title":"International Classification of Headache Disorders, 3rd Edition","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","journal-title":"Cephalalgia"},{"issue":"10","key":"e_1_2_10_22_1","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1177\/0333102420941839","article-title":"Guidelines of the International Headache Society for Controlled Trials of Preventive Treatment of Migraine Attacks in Episodic Migraine in Adults","volume":"40","author":"Diener H.\u2010C.","year":"2020","journal-title":"Cephalalgia"},{"issue":"5","key":"e_1_2_10_23_1","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1177\/0333102418758283","article-title":"Guidelines of the International Headache Society for Controlled Trials of Preventive Treatment of Chronic Migraine in Adults","volume":"38","author":"Tassorelli C.","year":"2018","journal-title":"Cephalalgia"},{"key":"e_1_2_10_24_1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jchromb.2018.04.038","article-title":"Quantification of 21 Antihypertensive Drugs in Serum Using UHPLC\u2010MS\/MS","volume":"1089","author":"Gundersen P. O. M.","year":"2018","journal-title":"Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences"},{"key":"e_1_2_10_25_1","unstructured":"ISO (The International Organization for Standardization).ISO\/IEC 17025:2017(en) General Requirements for the Competence of Testing and Calibration Laboratories.2017."},{"key":"e_1_2_10_26_1","unstructured":"Norwegian Accreditation.NA Dok. Nr. 48a2017."},{"key":"e_1_2_10_27_1","unstructured":"Sciences TSoFTIaTAAoF.Toxicology Section: SOFT AAFS Forensic Laboratory Guidelines 2006 Final.2006."},{"key":"e_1_2_10_28_1","unstructured":"U.S. Department of Health and Human Services FaDA Center for Drug Evaluation and Research (CDER)andCenter for Veterinary Medicine (CVM)Bioanalytical Method Validation \u2010 Guidance for Industry.2018."},{"issue":"3","key":"e_1_2_10_29_1","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/bcpt.13703","article-title":"Metformin Serum Concentrations During Pregnancy and Post Partum \u2010 A Clinical Study in Patients With Polycystic Ovary Syndrome","volume":"130","author":"Espnes K. A.","year":"2022","journal-title":"Basic & Clinical Pharmacology & Toxicology"},{"issue":"2","key":"e_1_2_10_30_1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/FTD.0000000000001264","article-title":"How to Determine a Therapeutic Reference Range for a Psychotropic Drug Systematically? Recommendations of the TDM Task Force of the AGNP","volume":"47","author":"Hart X. M.","year":"2025","journal-title":"Therapeutic Drug Monitoring"},{"issue":"1","key":"e_1_2_10_31_1","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/FTD.0000000000000806","article-title":"Establishing Serum Reference Ranges for Antihypertensive Drugs","volume":"43","author":"Rognstad S.","year":"2021","journal-title":"Therapeutic Drug Monitoring"},{"issue":"5","key":"e_1_2_10_32_1","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.clpt.2003.08.001","article-title":"Altered Pharmacokinetics and Excessive Hypotensive Effect of Candesartan in a Patient With the CYP2C91\/3 Genotype","volume":"74","author":"Uchida S.","year":"2003","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"12","key":"e_1_2_10_33_1","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s00228-010-0864-8","article-title":"Linkage Disequilibrium Between the CYP2C19*17 Allele and Wildtype CYP2C8 and CYP2C9 Alleles: Identification of CYP2C Haplotypes in Healthy Nordic Populations","volume":"66","author":"Pedersen R. S.","year":"2010","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"3","key":"e_1_2_10_34_1","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/FTD.0000000000000585","article-title":"A Compilation of Serum Concentrations of 12 Antipsychotic Drugs in a Therapeutic Drug Monitoring Setting","volume":"41","author":"J\u00f6nsson A. K.","year":"2019","journal-title":"Therapeutic Drug Monitoring"},{"issue":"2","key":"e_1_2_10_35_1","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/FTD.0000000000001263","article-title":"Therapeutic Drug Monitoring of Psychotropic Drugs: What We Know, What We Don't, and the Controversies","volume":"47","author":"Spigset O.","year":"2025","journal-title":"Therapeutic Drug Monitoring"}],"container-title":["Basic &amp; Clinical Pharmacology &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcpt.70322","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcpt.70322","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcpt.70322","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:16:29Z","timestamp":1791846989000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bcpt.70322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10.1111\/bcpt.70322"],"URL":"https:\/\/doi.org\/10.1111\/bcpt.70322","archive":["Portico"],"relation":{},"ISSN":["1742-7835","1742-7843"],"issn-type":[{"value":"1742-7835","type":"print"},{"value":"1742-7843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"assertion":[{"value":"2026-05-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70322"}}